The SocietyMore than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS communityBecome an ERS member
TB constitutes a public health problem at a global level. It’s essential that professionals are well aware of the strategies and solutions for the challenges that TB entails. The End TB Strategy by the WHO calls on governments to commit to the adaptation and implementation of this strategy, relying not only on the health sector, but seeking to comprise a multisectorial effort that’s able to end TB on a global scale.
Educational aims
Build knowledge of healthcare professionals and other professionals on epidemiological traits of TB on a global scale;
Have the confidence to devise and develop strategies that are able to lessen the burden of TB;
Understand the premises and topics underlying the End TB Strategy and which efforts could be undertaken in order to compromise with the targets established by the WHO
Topics/Programme
Epidemiology of TB (estimates of incidence, mortality, drug-resistant TB estimates, TB/HIV);
International targets and progress towards them;
New challenges and strategies to move forward;
Global End TB Strategy to face the challenge;
Q&A
Learning outcomes
Following the webinar, participants will be able to:
Understand the global impact of TB, through epidemiological concepts;
Transpose epidemiological concepts of TB to clinical practice;
Understand the global challenges of TB;
Develop strategies that will allow to lessen the burden of TB;
Understand the premises underlying the End TB Strategy and its implications for clinical practice.
Format
Panel discussion divided into two parts (of approximately 30 min each):
Presentation on the global burden of TB (Mario Raviglione)
Open discussion and Q&A (moderated by chairs)
UNITE4TB is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. The 7-year, €185 million project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active Tuberculosis (TB) treatment regimens for drug-resistant and -sensitive TB. For more information, visit the consortium website: unite4TB.org
The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. For further information: imi.europa.eu
This communication reflects the author’s view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.”
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.